Assembly Biosciences, Inc.ASMBNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank49
5Y CAGR-30.3%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
-30.3%/yr
Long-term compound
Percentile
P49
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 4.00% |
| Q3 2025 | 2.87% |
| Q2 2025 | 8.58% |
| Q1 2025 | 4.00% |
| Q4 2024 | 5.66% |
| Q3 2024 | -16.88% |
| Q2 2024 | 36.87% |
| Q1 2024 | 7.93% |
| Q4 2023 | 1.68% |
| Q3 2023 | -13.57% |
| Q2 2023 | -13.91% |
| Q1 2023 | -13.68% |
| Q4 2022 | -7.04% |
| Q3 2022 | 1.90% |
| Q2 2022 | 3.41% |
| Q1 2022 | 16.67% |
| Q4 2021 | -20.17% |
| Q3 2021 | 10.30% |
| Q2 2021 | -2.65% |
| Q1 2021 | -48.66% |
| Q4 2020 | 24.38% |
| Q3 2020 | 15.49% |
| Q2 2020 | 1.22% |
| Q1 2020 | 1.90% |
| Q4 2019 | 4.05% |
| Q3 2019 | 16.24% |
| Q2 2019 | -17.64% |
| Q1 2019 | 6.84% |
| Q4 2018 | 11.21% |
| Q3 2018 | 7.11% |
| Q2 2018 | 22.69% |
| Q1 2018 | 37.22% |
| Q4 2017 | -3.04% |
| Q3 2017 | -9.86% |
| Q2 2017 | 14.67% |
| Q1 2017 | 22.63% |
| Q4 2016 | -2.39% |
| Q3 2016 | 17.48% |
| Q2 2016 | -7.38% |
| Q1 2016 | 55.36% |